Following successful development of CAR-T therapies targeting CD19 for refractory non-Hodgkin’s B-cell lymphoma (B-NHL) and B-cell acute lymphoblastic leukaemia (B-ALL), a CAR T-cell therapy targeting B-cell maturation antigen (BCMA) in MM was developed [47,48]. Here, TNFRSF17 is linked to Miyoshi myopathy.